Balloon Guide Catheter Combined With Filter Protection for Carotid Artery Stenting

NCT ID: NCT07247864

Last Updated: 2025-12-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

296 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-03

Study Completion Date

2027-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This multicenter, randomized, controlled trial evaluates a combined embolic protection strategy during carotid artery stenting (CAS). Carotid artery stenosis is a major cause of stroke. While stenting is an effective treatment, the procedure itself carries a risk of dislodging plaque debris, which can travel to the brain and cause new strokes or silent brain infarctions.

Currently, a distal filter (protection device) is standardly used to catch debris. However, it may not capture all particles. This study investigates whether adding a Balloon Guide Catheter (BGC)-which temporarily stops blood flow and allows for aspiration-to the standard filter protection is more effective than using the filter alone.

Patients with symptomatic (≥50% stenosis) or asymptomatic (≥70% stenosis) carotid artery stenosis who are scheduled for stenting will be randomly assigned to one of two groups:

1. Combined Protection Group: Receiving CAS using a Balloon Guide Catheter combined with a distal filter.
2. Standard Protection Group: Receiving CAS using a distal filter alone. The primary goal is to determine if the combined approach reduces the number of new ischemic lesions detected on brain MRI within 72 hours post-procedure. The study will also assess clinical stroke events over a 90-day follow-up period.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carotid Artery Stenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Combined Protection Group (BGC + Filter)

Patients in this group will undergo carotid artery stenting (CAS) using a Balloon Guide Catheter (BGC) for proximal protection combined with a distal filter protection device.

Group Type EXPERIMENTAL

Balloon Guide Catheter

Intervention Type DEVICE

A catheter with a balloon at the distal tip, used to temporarily arrest flow and aspirate debris during the stenting procedure.

Distal Filter Protection Device

Intervention Type DEVICE

A mesh-type device deployed distally to the stenosis to capture embolic debris during the procedure.

Standard Protection Group (Filter Alone)

Patients in this group will undergo carotid artery stenting (CAS) using a standard guiding catheter and a distal filter protection device alone.

Group Type ACTIVE_COMPARATOR

Distal Filter Protection Device

Intervention Type DEVICE

A mesh-type device deployed distally to the stenosis to capture embolic debris during the procedure.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Balloon Guide Catheter

A catheter with a balloon at the distal tip, used to temporarily arrest flow and aspirate debris during the stenting procedure.

Intervention Type DEVICE

Distal Filter Protection Device

A mesh-type device deployed distally to the stenosis to capture embolic debris during the procedure.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BGC Embolic Protection Device EPD

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age 18 years or older.
2. Diagnosis of extracranial carotid artery stenosis meeting one of the following criteria (measured by DSA or CTA using NASCET criteria):

Symptomatic: TIA or non-disabling stroke in the ipsilateral carotid distribution within the past 6 months, with stenosis ≥ 50%.

Asymptomatic: Stenosis ≥ 70%, with indication for interventional therapy.
3. Pre-treatment Modified Rankin Scale (mRS) score of 0 to 1.
4. Scheduled for carotid artery stenting (CAS) as determined by the clinical team.
5. Signed informed consent provided by the patient or their legal representative.

Exclusion Criteria

1. Occlusion of the contralateral internal carotid artery (ICA).
2. Severe stenosis of the contralateral common carotid artery (CCA) or internal carotid artery (ICA).
3. Occlusion of the ipsilateral external carotid artery (ECA).
4. Severe stenosis of the ipsilateral intracranial segment of the internal carotid artery.
5. Severe stenosis of the vertebrobasilar artery system (excluding non-dominant vertebral artery).
6. History of previous stenting in the head or neck vessels.
7. Presence of other cerebrovascular diseases, such as intracranial aneurysms \> 5 mm or vascular malformations.
8. Stroke onset within the last 7 days.
9. Pregnant or lactating women.
10. Known allergy to contrast media or stent materials (e.g., Nitinol).
11. Previous large cerebral infarction with sequelae that would interfere with the assessment of endpoint events.
12. Absolute or relative contraindications to antiplatelet therapy.
13. Clear risk of cardioembolism (e.g., atrial fibrillation, atrial flutter, intracardiac thrombus) or clear indication for anticoagulation therapy.
14. Life expectancy of less than 1 year.
15. Pre-existing neurological or psychiatric diseases that would confound neurological assessment (e.g., severe dementia).
16. Severe renal insufficiency (Glomerular Filtration Rate \[GFR\] \< 30 ml/min).
17. Contraindications to Magnetic Resonance Imaging (MRI).
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Beijing Anzhen Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Xiaochuan Huo

Director

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Beijing Anzhen Hospital Affiliated to Capital Medical University

Beijing, Beijing Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Xiaochuan Huo, Doctor, Doctor

Role: CONTACT

+86 13716292262

Xin Tong, Doctor

Role: CONTACT

+86 17810651085

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Xiaochuan Huo, Doctor

Role: primary

+86 13716292262

Xin Tong, Doctor

Role: backup

+86 17810651085

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KS2025109

Identifier Type: -

Identifier Source: org_study_id